Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Eagle Capital Growth Fund (GRF)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.75 +3.87%
on 07/16/19
8.09 -0.49%
on 07/08/19
+0.24 (+3.12%)
since 06/19/19
3-Month
7.10 +13.38%
on 05/29/19
8.09 -0.49%
on 07/08/19
+0.29 (+3.74%)
since 04/18/19
52-Week
6.55 +22.90%
on 12/31/18
8.39 -4.05%
on 07/25/18
+0.04 (+0.50%)
since 07/19/18

Most Recent Stories

More News
Grifols presents additional encouraging Alzheimer's trial results at AAIC

The Grifols Clinical Research team, led by Dr. Antonio Páez, today presented additional results of its AMBAR (Alzheimer Management by Albumin Replacement) clinical trial for the treatment of Alzheimer's...

GRFS : 22.12 (-0.14%)
GRF : 8.05 (+1.13%)
Grifols Announces FDA Approval of Xembify®, 20% Subcutaneous Immunoglobulin for Primary Immunodeficiencies

Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ: GRFS), a leading global producer of plasma-derived medicines, announced today that Xembify®, its new 20% subcutaneous immunoglobulin, has been approved by the U.S....

GRFS : 22.12 (-0.14%)
GRF : 8.05 (+1.13%)
Grifols Announces FDA Approval of Xembify®, 20% Subcutaneous Immunoglobulin for Primary Immunodeficiencies

BARCELONA, Spain , July 4, 2019 /PRNewswire/ -- Grifols (MCE:GRF) (MCE:GRF.P) (NASDAQ: GRFS), a leading global producer of plasma-derived medicines, announced today that Xembify ® , its new...

GRFS : 22.12 (-0.14%)
GRF : 8.05 (+1.13%)
Grifols Selected to Build Its First Intravenous Solutions Manufacturing Line in Africa

Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced it has been selected by Soludia Maghreb,...

GRFS : 22.12 (-0.14%)
GRF : 8.05 (+1.13%)
Grifols Selected to Build Its First Intravenous Solutions Manufacturing Line in Africa

BARCELONA, Spain , July 3, 2019 /PRNewswire/ -- Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases,...

GRFS : 22.12 (-0.14%)
GRF : 8.05 (+1.13%)
GIKLY : 15.5500 (unch)
Grifols Announces the Opening of its new Plasma Donor Center in Hinesville, Georgia

Grifols is pleased to announce the opening of a new Biotest plasma donor center located at 108 West Hendry Street, Hinesville, Georgia. The 11,000 square foot state-of-the-art facility officially opened...

GRFS : 22.12 (-0.14%)
GRF : 8.05 (+1.13%)
Grifols donations of blood clotting factor helping people with hemophilia globally

Grifols, one of the world's three top providers of plasma-derived medicines to treat life-threatening diseases, today announced that its long-term global initiative to providing treatment to people with...

GRFS : 22.12 (-0.14%)
GRF : 8.05 (+1.13%)
Grifols 2018 Annual Report on Form 20-F Filed With the SEC on April 5, 2019

Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS) announced that it has filed its 2018 Annual Report on Form 20-F with the United States Securities and Exchange Commission ("SEC") on April...

GRFS : 22.12 (-0.14%)
GRF : 8.05 (+1.13%)
Grifols 2018 Annual Report on Form 20-F Filed With the SEC on April 5, 2019

GIFOF : 21.5843 (+0.42%)
GIFLF : 32.2000 (+8.55%)
GRFS : 22.12 (-0.14%)
GRF : 8.05 (+1.13%)
GIKLY : 15.5500 (unch)
Grifols Announces the Opening of its new Plasma Donor Center in Russellville, AR

Grifols is pleased to announce the opening of a new Biotest plasma donor center located at 1105 W Main Street, Russellville, Arkansas. The 15,000 square foot state-of-the-art facility officially opened...

GRFS : 22.12 (-0.14%)
GRF : 8.05 (+1.13%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

GRF Dividends

Date Value
11/21/18 $0.5300
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar